New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:12 EDTNWBONorthwest Biotherapeutics reports initial positive data in cancer candidate tria
Northwest Biotherapeutics provided an initial patient case study, showing signs of tumor necrosis or death and initial tumor regression, from the company's ongoing DCVax-Direct trial for all types of inoperable solid tumors. The company continues collecting data from the trial. The specific case study involves a sarcoma patient with a large tumor mass and multiple inoperable metastatic tumors in the lung. This patient's results suggest both local and systemic effects of the DCVax-Direct treatment, as were seen in the pre-clinical studies. These results were further supported by tumor biopsies taken at the time of the most recent injection, which showed a high rate of tumor necrosis and appearance of T cells infiltrating into the injected tumor. The company is currently conducting a 60-patient Phase I/II trial with DCVax-Direct for all types of inoperable solid tumors.
News For NWBO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
09:35 EDTNWBOWoodford turns activist on Northwest Biotherapeutics
Woodford Investment Management transitioned from a passive investor to an active shareholder in Northwest Biotherapeutics after sending a letter to the company's board requesting an independent non-executive director be appointed. In a letter to the board disclosed last night in a regulatory filing, Neil Woodford of Woodford Investment stated, "I am writing to ask you to formally accept our proposal to appoint an independent non-executive director to the Board. As we have stated, we believe that, at your current stage of development, the Company and its shareholders would greatly benefit from the appointment of one or more directors with the skills and experience to provide significant contributions and oversight to the Company's operations and growth." Woodford has also engaged Freeh Group International Solutions to provide risk management services in relation to its investment in Northwest Bio. "These services include the provision of a suitably qualified candidate, Mr Elliott Leary, for appointment to the Company's Board. Following your agreement in principle to this proposal on 13 November, 2015, we submitted a highly qualified candidate who met with the Board last week," the letter to the board stated. Woodford explained, "We believe the candidate's skills are especially suited to the current situation of the Company in relation to the various allegations of financial improprieties and regulatory failure that have been published by at least one anonymous source. We would like to note that we only became aware of certain of these allegations after the completion of our recent investment in the Company comprising US $30 million in new equity." Woodford Investment owns 28.1% of Northwest's outstanding shares. The stock is up 5c to $5.01 in early trading.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use